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Abstract
Introduction: Idiopathic normal pressure hydrocephalus (iNPH) is characterized by 
dilated cerebral ventricles with progressive impaired gait, cognition, and urinary control. 
Firstly described in 1965 by Hakim and Adam, it remains largely under-diagnosed. The 
diagnosis is based on clinical and imaging (CT or MRI) investigations; a timely diagnosis 
and cerebrospinal fluid (CSF) shunt surgery has reported to be beneficial in 60 up to 80% 
of the cases.
Body: The severity of motor and cognitive disturbances varies widely and it can be dif-
ficult to distinguish iNPH from other neurodegenerative disorders. The cognitive and 
behavioral disturbances have been commonly described as “fronto-subcortical dys-
function”. However, this definition is reductive not encompassing the entire cognitive 
spectrum of iNPH deficits. In our sample we found an impairment in respect to healthy 
controls in all the neuropsychological tests, but verbal memory. We could also find a 
positive correlation between the severity of cognition deficit and disease progression, 
suggesting a common pathological mechanism.
Conclusions: iNPH  can be reliably diagnosed with an organized approach. Neurologists 
play an essential role in the care of patients and a multidisciplinary team can improve this 
process. An early shunt surgery might contain the progression of the disturbances and 
also possibly prevent their development.
Keywords: hydrocephalus, neurodegenerative diseases, cognition, aging and dementia, 
neurogeriatric
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1. Introduction
Idiopathic normal pressure hydrocephalus (iNPH) was described for the first time in 1965 by 
Hakim and Adam as ventricular dilation accompanied by a progressive triad of a gait distur-
bance, “dementia” and incontinence. Usually gait and balance disorders appear early and are 
the most impressive symptoms, cognitive decline and incontinence generally appear later as 
the disease progresses [1].
The symptoms presented usually appear as:
• Gait disturbances as apraxia or that are commonly seen in parkinsonism (bradykinetic, 
magnetic and shuffling gait).
• Urinary incontinence: urinary frequency, urgency, or frank incontinence.
• Dementia: executive dysfunction, psychomotor slowing, prominent memory loss, visuo-
spatial difficulties, decreased attention, apathy.
The gait disturbance is typically the earliest feature noted and is considered to be the most 
responsive to treatment. The primary feature is thought to resemble an apraxia of gait or a 
“lower body parkinsonism”. True weakness or ataxia is typically not observed. The severity 
of gait disorders range from mild to the wheelchair.
The urinary symptoms of NPH can present as urinary frequency, urgency, or incontinence. 
While incontinence can result from gait disturbance and dementia, in a study by Sakakibara and 
colleagues [2] 95% of patients had urodynamic parameters consistent with detrusor overactivity.
The cognitive and behavioral disturbances accompanying iNPH have been commonly 
described as “fronto-subcortical dysfunction”.
However, this definition is reductive not encompassing the entire cognitive spectrum of iNPH 
deficits. We will deal with this topic more in detail later on.
The incidence of iNPH is between 2 and 6% among people affected by any dementia condi-
tion; its occurrence is probably underestimated. Brean and Eide [3] reported a prevalence of 
21.9/100,000 and an incidence of 5.5/100,000 in a Norwegian population, which are probably 
minimum estimates according to the authors.
A more recent epidemiological study [4] confirms this impression: the prevalence of prob-
able iNPH has been reported to be 0.2% in subjects aged 70–79 years and 5.9% in those aged 
80 years and older, respectively, without difference between men and women. Moreover, 
as the authors wrote: “the number of subjects with iNPH is probably much higher than the 
number of persons currently treated”, and since the prevalence increases with increasing age 
they estimate approximately that 2 million persons in Europe and 700,000 in the United States 
may have iNPH.
A high incidence was also reported by Iseki et al. [5] in a 10-year follow-up study of a popula-
tion of 70 year olds from a rural Japanese community. A recent systematic epidemiological 
review [6] confirmed that this pathology is under-diagnosed.
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The need for guidelines and operating criteria for the diagnosis and management of this con-
dition was firstly implemented by the Japanese Society of Normal Pressure Hydrocephalus 
in 2004; as the paper however was available only in Japanese, in 2005 Marmarou et al. [7] 
published English language guidelines designed to be “acceptable in the United States and 
abroad”. Then, as there were some differences between the two guidelines, International and 
Japanese, in 2008 Ishikawa et al. [8] proposed an English and up to date version of the previ-
ous Japanese guidelines in order to make them known worldwide.
Finally, in 2012, given the significant increase in basic and clinical research on iNPH and the 
availability of more high level evidence, Mori et al. [9] published a revision of the English 
language version of the Japanese guidelines.
More recently, Williams and Relkin [1] have published detailed indications on the diagnosis 
and management of iNPH; on the basis of an extremely clinical approach, the authors stress the 
concept that the starting point should be a comprehensive history and neurological examina-
tion, review of neuroimaging studies, and evaluation of the differential diagnosis. Moreover, 
the article reports a comparison between the International and Japanese Guidelines, where 
the former are more exhaustive regarding the clinical features.
2. Imaging studies
In most cases of new onset of neurologic symptoms, a computerized tomography (CT) scan 
of the brain is initially obtained. Although magnetic resonance imaging (MRI) is more specific 
than CT in iNPH, a normal CT scan can exclude the diagnosis. As shown in Figure 1 MRI 
findings in iNPH include the following:
• ventricular enlargement out of proportion to sulcal atrophy, with typical rounding of fron-
tal horns
• prominent periventricular hyperintensity consistent with transependymal flow of CSF 
and/or leukoaraiosis
• aqueduct perviety (or slight enlargement) to exclude congenital stenosis. A more specific sign, 
prominent flow void in the aqueduct, the so-called hyperdynamic aqueduct or jet sign, requires 
spine-echo sequences, currently dismissed in routine MRI, replaced by the faster turbo-spin-
echo sequences, (Today, a confirmation of the hyperdynamic aqueduct should be obtained 
by measuring aqueduct cerebral spinal flow (CSF) stroke volume by phase-contrast MRI [10]
• thinning and elevation of corpus callosum on the median sagittal slice, and acute callosal 
angle in the coronal slice passing through the posterior commissure [11].
A narrow CSF space at the high convexity/midline areas relative to Sylvian fissure size was 
recently shown to correlate with a diagnosis of probable or definite iNPH. This specific sign, 
called “Disproportionally enlarged Subarachnoid spaces Hydrocephalus” (DESH) [12] has 
been found the most sensitive to the ventricular shunting. To establish a diagnosis of NPH, an 
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MRI or CT must show an Evans index of at least 0.3 [13]. In addition, to exclude hydrocepha-
lus ex vacuo, one or more of the following must also be present:
• disproportionally enlarged subarachnoid spaces hydrocephalus (DESH)
• acute callosal angle
• hyperdynamic aqueduct.
• Pathophysiology
Figure 1. A: Axial FLAIR shows periventricular white matter changes, ventricles dilatation in both frontal and occipital 
horns, Evan’s index >0.30 B: Axial FLAIR at upper level shows global sulcal thinning and focal sulcal dilatation C coronal 
T2 shows acute callosal angle and disproportionally enlarged subarachnoidal spaces hydrocephalus (DESH) D sagittal 
T1 shows callosal bulging and mild aqueduct enlargement.
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The pathophysiology of iNPH is still not completely understood. iNPH differs from other 
causes of adult hydrocephalus, in which pathological changes alter the pressure of the cere-
brospinal fluid (CSF), but it is also related to alterations of the CSF dynamicity [14].
The CSF space is a dynamic system, which constantly adapts its pressure to keep it constant. It 
responds to changes in CSF formation or reabsorption rates, arterial and venous flow, compli-
ance of the intracranial structures and fluctuations in intracranial pressure (ICP). This process 
is essential for ensure the correct functioning of the brain. Indeed, the brain is enclosed in a 
fixed structure and any volume increase needs to be matched by a decrease to avoid changes 
of the intracranial pressure and consequential functional abnormalities.
The volume of blood entering the brain varies with the cardiac cycle, being present a net intra-
cranial inflow of blood during systole and a net outflow during diastole. Arterial supply to the 
brain is pulsatile while venous flow is not, and this mismatch generates transient rises in CSF 
pressure. The system compensates for this in two different ways. First, the blood vessels can 
smooth the arterial blood influx modulating their compliance. Second, the CSF flows through 
the cerebral aqueduct in response to pulsatile blood flow, thus maintaining intracranial pres-
sure stable. When these processes are altered, compensatory strategies are applied. However, 
the compensatory mechanisms that keep the CSF pressure constant may also produce other 
pathological alteration [14].
In iNPH, the compliance of the system is reduced, especially in the vessel of the superior sag-
ittal sinus [15, 16]. This lack of arterial compliance is initially countered by increased pulsatile 
CSF flow through the aqueduct, but as the amplitude of arterial pulsatility increases, the blood 
flow in systole induces large ICP pulsations, determining the ‘water hammer’ effect. These 
exaggerated pulsations cause venous damage in the periventricular region and displace the 
brain toward the skull [17], thus determining the development of the hydrocephalus. Indeed, 
hydrocephalus occurs as a result of enlarging ventricles at the expense of a reduced subarach-
noid space. This is secondary to increasing pressure within the ventricles directed toward the 
subarachnoid space, namely as increase of the transmantle pressure (i.e., the pressure gradi-
ent between the ventricles and the subarachnoid space) [17].
This pressure gradient also explains why, although there is increased intraventricular pres-
sure, the measured opening pressure during a lumbar puncture is within normal limits. It also 
implies that ‘normal pressure’ in NPH is somewhat of a misnomer [14].
It is still unclear what triggers the initial reduction in arterial compliance. Deep white mat-
ter ischaemia surrounding arterioles may explain the loss of autoregulation [18].When the 
arterioles are obstructed, venous collapse ensues, followed by impaired CSF drainage and 
ventricular enlargement [18].
Evidence points also to an altered cerebral blood flow (CBF), which may favor such perivasal 
ischemia. It has been described a strong association between impaired CBF and iNPH. Patients 
with iNPH are more likely to have concomitant cerebrovascular disease [19]. MRI shows 
increased white matter changes (WMCs) [20] and this is further supported by neuropatho-
logical studies showing microvascular alterations [21, 22]. Age-related vascular changes can 
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directly cause the reduction in vascular compliance [23]; this could explain the association 
between NPH and vascular disease.
Alternatively, it has been proposed that increased transvenular resistance in the territory of 
the superior sagittal sinus can act as trigger in iNPH. Indeed, it might be that the majority of 
CSF resorption occurs through the brain parenchyma and not at the level of the arachnoid 
villi or arachnoid granulations [17, 24, 25]. In this view, CSF resorption would be affected with 
increased transvenular resistance.
CSF outflow resistance has been investigated in few studies, which reported an abnormal 
outflow in animal models and subjects with in iNPH [26, 27].
More recently, the new concept of glymphatic system has been introduced [28, 29]. The 
glymphatic system is a macroscopic waste clearance system which utilizes a unique sys-
tem of perivascular tunnels formed by astroglial cells to promote the elimination of soluble 
proteins and metabolites from the central nervous system. It also facilitates brain-wide dis-
tribution of several compounds including glucose, lipids, amino acids, growth factors and 
neuromodulators; interestingly it functions mainly during sleep. The glymphatic system has 
been proposed to be instrumental in normal aging and brain pathology; in particular altered 
glymphatic function in iNPH could possibly be a mechanism behind the high comorbidity 
between iNPH and Alzheimer’s disease [30]. A reduced glymphatic clearance has been found 
in a MRI study in iNPH and interpreted as instrumental for the development of dementia in 
this disease [29].
Further data suggest that aquaporin-4 channels can be implicated in the pathophysiology of 
iNPH [31]. Aquaporin-4 channels are transmembrane proteins that facilitate water transport 
in the brain and play roles in fluid secretion, cell migration, brain edema, metabolism, and 
many aspects of cell homeostasis; a modulation of their activity could be a potential target for 
pharmacological management of iNPH.
Lastly, also neurodegeneration might play a role in iNPH development as suggested by the 
high levels of tau protein in CSF of iNPH patients [32], as detailed below.
In conclusion, there is still a debate on the different theories of iNPH pathogenesis, even if it 
must be stressed that these theories may not be mutually exclusive [33]. Besides the possible 
mechanisms, it should be stressed out that many (although not all) of the clinical symptoms 
are reversible if patients are early recognized and correctly treated. The fostering of an early 
diagnosis is a great need, but must match the clinical accuracy.
3. Diagnostic considerations
Many other illnesses can mimic iNPH and therefore have to be distinguished. Regarding 
in particular the motor disturbances, the most frequent disease in differential diagnosis is 
Parkinson’s disease; start hesitation and freezing episodes can occur in iNPH similar to the gait 
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in Parkinson disease, however rest tremor and usually unilateral symptoms onset  typical of 
Parkinson’s disease are less commonly observed in iNPH. Furthermore, in iNPH the response 
to the therapy with levodopa is usually scarce. The differential diagnosis can be particularly 
challenging in case of vascular dementia with small vessels disease or atypical parkinsonisms, 
Progressive supranuclear palsy in particular [34]. The differential diagnosis with AD will be 
treated below.
In their paper Williams, Relkin [1] report a precise analysis of differential diagnosis. Each of 
the primary symptoms of iNPH has in fact multiple potential etiologies (Table 1). It is quite 
uncommon to see patients affected by only iNPH because most of them have other conditions 
contributing to their symptoms. On the other hand, patients without iNPH may appear to 
have the iNPH syndrome because of multiple comorbidities.
Gait Dementia Incontinence
Disorders that may have all 3 symptoms
iNPH, with or without comorbidities X X X
Parkinsonism X X X
Lewy body dementia X X X
Corticobasal degeneration X X X
Progressive supranuclear palsy X X X
Multiple system atrophy X X X
Vascular dementia X X X
Neurosyphilis X X X
Medication side effects X X X
Multifactorial—any combination of diagnoses, with or without iNPH X X X
Disorders that may have 2 symptoms
Multifactorial—any combination of
diagnoses, with or without iNPH
X X X
iNPH, with or without comorbidities X X X
Vitamin B
12
 deficiency X X
Cervical stenosis and myelopathy X X
Lumbosacral stenosis X X
Peripheral neuropathy X X
Disorders that may have only one symptom
iNPH X
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Initially is important to identify or exclude other disorders that should be treated before eval-
uating iNPH. Although iNPH is described as a symptom “triad,” patients do not need to have 
all three symptoms. However, gait impairment is the symptom that affects nearly all patients 
as described by most published series and guidelines. A patient who has only dementia or 
incontinence should first be evaluated for other disorders. Patients with gait impairment and 
urinary symptoms but no cognitive impairment may need evaluation for spinal cord disor-
ders. Although any of the primary iNPH symptoms may be the initial symptom, gait impair-
ment is usually either the first or worst symptom.
Gait Dementia Incontinence
Degenerative arthritis of the hips,
knees, ankles
X
Spinocerebellar degeneration X
Peripheral vascular disease
(claudication)
X
Alzheimer dementia X
Frontotemporal dementia X
Depression X
Hypothyroidism X
Sleep apnea X
Prostatic hypertrophy/obstructive
uropathy
X
Pelvic-floor abnormalities X
Interstitial cystitis X
Disorders that can aggravate other
symptoms
Visual impairment X X
Hearing impairment X
Obesity X
Cardiovascular disease X
Pulmonary disease X
Chronic lower-back pain X
Vestibular disorders X
Table 1. Differential diagnosis of idiopathic normal pressure hydrocephalus (iNPH). Taken from [1].
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4. Management
Even though research in this field has advanced, iNPH still has to be considered a complex 
pathology whose diagnosis and management continue to present many problems. The main 
interest is represented by the fact that iNPH can be considered a potentially reversible demen-
tia. Surgical diversion of CSF via a shunt remains the main treatment for this condition. This 
is based on the presumption that CSF diversion will reduce or normalize the transmantle 
pressure, thereby stabilizing or improving symptoms [14].
Ventriculo-peritoneal (VP) shunts are the most commonly used [35]; in Japan iNPH is treated 
mainly with lumboperitoneal (LP) shunts and in the last years also in Western Countries this 
procedure has began to be adopted. The data are still scarce, but LP shunts seem to have 
effectiveness rates similar to those of VP shunts. Despite greater rates of device-related com-
plications, LP shunting can be recommended for the treatment of patients with iNPH because 
of their minimal invasiveness and lack of the lethal complications seen with VP shunts [36].
It must be stressed out that not all patients with iNPH are candidate for shunt surgery. The 
risk-to-benefit ratio has to be assessed individually. Prior to embarking upon surgical ther-
apy, knowing which patients may benefit from surgery is necessary. All patients with sus-
pected iNPH should undergo diagnostic CSF removal (either large-volume lumbar puncture 
and/or external lumbar drainage), which has both diagnostic and prognostic value. Detailed 
testing is performed before and after CSF drainage; improvement in motor symptoms after 
large-volume drainage supports the diagnosis of iNPH, while improvement does not rule 
out iNPH. Recently, a novel standardized paradigm with a simultaneous quantification of 
cognition and gait (dual task gait assessment and mental imagery of locomotion) before and 
24 h after CSF tapping has been proposed [37], which can contribute to the identification 
of patients with iNPH from its mimics. The same authors underline the major limitation of 
this paradigm (i.e. an expansive and time-consuming evaluation), however it responds to the 
need of standardized evaluative parameters. Moreover, a levodopa challenge may be helpful 
to rule out idiopathic Parkinson disease; patients with iNPH have no significant response to 
levodopa or dopamine agonists.
The best candidates for shunt surgery would show imaging evidence of ventriculomegaly, 
indicated by a frontal horn ratio exceeding 0.30 on imaging studies, with one or more of the 
following criteria, as indicated by Schneck [38]:
• Presence of a clearly identified etiology.
• Predominant gait difficulties with mild or absent cognitive impairment.
• Substantial improvement after CSF withdrawal (CSF tap test or lumbar drainage).
• Normal-sized or occluded sylvian fissures and cortical sulci on CT scan or MRI.
• Absent or moderate white matter lesions on MRI.
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Specific criteria and guidelines have been defined for the surgical procedure and the post-
operative and long-term care, including the management of complications [7, 9], even if a 
consensus measurement of CSF shunting outcome is still lacking [14].
Many studies have investigated the benefit of shunt surgery. Only one assessed the ben-
efit of shunting surgery in a randomized manner and showed that, among the 14 patients 
included, only those with CSF shunts improved at 3 months follow-up. In particular, the 
patients with effective (open) shunts showed an improvement in motor and psychometric 
scores (30 and 23% increase, respectively) at 3 months, whereas those with placebo (ligated) 
shunts were unchanged. Of note, this latter group also improved after opening the shunts, 
although with less benefit (28 and 18%, respectively) [39].This rate of benefit is in line with 
the results of a systematic review, which reported a long-term response of 29% [40]. A dou-
ble-blind randomized trial on the clinical effect of different shunt valve settings was also 
performed [41]; improvement after shunt surgery was evident within 3 months, irrespective 
of valve setting.
Recent studies showed higher rates of success (around 80–90%) [42, 43]; all these outcomes 
must be interpreted with caution, given the lack of standardized method of comparison. 
Besides the possible benefit, information about the risks of complications should also be pro-
vided, since they appear to be very common [44].
The complication ratio of CSF shunt was found on average of 38%. Potential complications 
include infection, seizures, abdominal problems (peritonitis, perforation, volvulus, and asci-
tes), shunt failure or blockage, shunt over-drainage and intracranial hemorrhage. The most 
common complication was the shunt over-drainage occurring in up to one-third of the patients 
within the first year [40]. Of course, the complication rates differ across centers. The Eu-iNPH 
study revealed a complication rate of 28% [42], while a recent study over more 230 subjects 
found a complication rate of less than 12% [43].
In any case, the clinical follow-up of the patients is essential. The follow-up helps the man-
agement of the complication, identifying the patients who need adjustments or revision of 
the shunt. Repeated brain imaging is usually performed after shunting and can support the 
identification and early treatment of subdural hemorrhage [14].
As previously reported, the response to levodopa/carbidopa is absent or scarce. In patients 
who are poor candidates for shunt surgery, repeated lumbar punctures in combination with 
acetazolamide may be considered [45]. Recent studies on aquaporin-4 channels suggest inter-
esting perspectives for future pharmacological treatment of iNPH [31].
5. Cognitive impairment in iNPH
The cognitive and behavioral disturbances accompanying iNPH have been commonly described 
as “fronto- subcortical dementia” [46, 47]. This clinical term is used to refer to a pattern of  mental 
decline, characterized by executive dysfunction, psychomotor slowing and mood symptoms, 
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especially apathy [48, 49], that is often present in patients with iNPH. However, as it will be 
detailed in this chapter, a wide range of other cognitive disturbances beside frontal involve-
ment can be detected.
Boon et al. [26] in a study evaluated global cognitive functioning, memory, and attention in a 
large sample (101 patients), reported that iNPH patients showed severe impairment of atten-
tion and psychomotor speed.
Iddon et al. [50], on the basis of Mini-Mental State Examination (MMSE) score cutoff, divided 
their sample of 11 patients into two groups: demented and non-demented. By the means of 
neuropsychological instruments which evaluated different cognitive functions, two cogni-
tive profiles in iNPH have been identified, one observed in patients at a less advanced dis-
ease stage, who presented isolated frontal lobe dysfunction, and the other observed in those 
who have reached a more advanced stage and presented severe global cognitive dysfunction. 
The non-demented iNPH patients obtained a worse performance on attentional tasks, thus 
suggesting a deficit in cognitive flexibility, similar to patients with frontal lobe excision and 
patients with fronto-subcortical dementia such as Parkinson’s disease [51, 52], and unlike 
patients with AD in which frontal functions usually are spared [53].
Ogino et al. [46], in a well-controlled study, analyzed 21 patients with iNPH and 42 patients 
with AD, using a neuropsychological assessment investigating different cognitive domains. 
iNPH patients had more severe impairment of attention, psychomotor speed and calcula-
tion than those with AD, while memory function and orientation were more preserved. 
Impairment in frontal functions in iNPH, but not in AD, was reported also by Miyoshi et al. 
[54], who compared the scores recorded on the Frontal Assessment Battery (FAB), on verbal 
fluency subtests and on subtests of the MMSE in patients with iNPH and AD, matched for 
age, sex, and MMSE score.
Tarnaris et al. [47], analyzing cognitive performances of 10 patients with iNPH through a 
complete neuropsychological assessment (language, memory, executive functions, visuo-
spatial abilities, and attention), confirmed that all the patients had subcortical cognitive 
impairment, characterized in particular by dysexecutive dysfunction and slowed mental 
processing.
Therefore, some studies have tried to relate the cognitive impairment in iNPH to damage the 
frontal lobe The results of single photon emission computed tomography and positron emis-
sion tomography (PET) studies showed that iNPH patients mainly presented hypoperfusion 
of the frontal lobe [55–57].
On the basis of the finding that periventricular white matter cerebral blood flow was reduced 
in iNPH [56] it has been suggested that the frontal lobe dysfunction might be secondary to 
a disturbance of the subcortical area connecting with the frontal lobe cortex [50, 57, 58]. The 
relatively preserved memory and orientation functions may be explained by a lower involve-
ment of memory systems, including the medial temporal lobe, in iNPH than in AD [46]. 
However, a neuroimaging study [59] demonstrated a reduction in the medial temporal vol-
ume in iNPH. Parietal regional cerebral blood flow reduction in iNPH has also been shown in 
other neuroimaging studies [60, 61].
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On the other hand, other studies have demonstrated that patients with iNPH can be impaired 
in broader cognitive domains; the definition of fronto-subcortical dementia has therefore to be 
considered reductive, given that the cognitive deficits observed in iNPH can extend beyond 
executive function, attention, working memory, and episodic memory to visuoperceptual and 
visuospatial functions [26, 56, 62, 63].
Saito et al. [64] evaluated 32 iNPH patients, 32 AD patients and 30 healthy elderly controls, 
using an extensive and comprehensive neuropsychological battery to investigate all the dif-
ferent cognitive domains: language, memory, executive functions, visuospatial and visuoper-
ceptual abilities, attention, and mental processing speed. Their results suggested that iNPH is 
associated with impairment in various aspects of cognition involving both frontal-executive 
and posterior-cortical functions, such as visuoperceptual and visuospatial abilities. In par-
ticular, defective performances were found on the visual discrimination and visual counting 
tasks; visuoperceptual and visuospatial abilities in iNPH patients were more severe than in 
those with AD, whereas the degree of memory impairment was comparable to that in AD 
patients.
The main involvement of visuospatial functions was observed also by Bugalho et al. [65]; 17 
iNPH patients have been compared with 14 healthy controls and the authors suggested that 
visuospatial deficits, and not executive dysfunction, could be an early sign of cognitive dete-
rioration in iNPH patients regardless of the severity of global cognitive dysfunctions.
Some studies, instead, focused on the nature of the memory deficit in order to identify a spe-
cific pattern. Walchenbach et al. [63] analyzed 51 iNPH patients, administering the MMSE and 
neuropsychological tests assessing both cortical (language, visuoperceptual skills and praxis, 
and memory functions) and fronto-subcortical functions (mental speed, concept shifting, and 
abstract reasoning). They suggested that the pattern of memory deficit in iNPH is of the fron-
tal lobe type, in which recall is disproportionately affected with respect to recognition, while 
in patients with AD recall and recognition are both impaired. Ogino et al. [46] observed mem-
ory impairment in iNPH, but they found that impairment of executive functions was more 
severe, while impairment of memory and orientation was milder in patients with iNPH than 
in those with AD. On the contrary, Saito et al. [64] found that both recognition and recall were 
impaired in a similar fashion both in iNPH and AD groups, thus suggesting that memory 
impairment in iNPH is not exclusively ascribable to frontal lobe dysfunction.
Therefore the data of the literature seem to confirm a wide range of cognitive decline in iNPH 
patients and according to Devito et al. [66] we can conclude that: “in some cases it may be 
qualitatively similar to normal aging, in others it may manifest as progressive dementia with 
gait disturbance, clinically similar to Alzheimer’s or Parkinson’s disease”.
However, there is no general agreement on the neuropsychological instruments to be used 
in assessing cognitive deficits. Bugalho et al. [65] employed a cognitive assessment protocol 
focused on various cognitive domains (global cognitive function, verbal memory, impulse 
control, verbal fluency, working memory, attention, visuospatial reasoning, and visuocon-
structive abilities) and also on mood and hand dexterity. Devito et al. [66] in a not recent but 
very interesting paper have reviewed possible application of clinical neuropsychology and 
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how it has contributed to our understanding of cognition in iNPH; they proposed a clinical 
assessment protocol in which beside cognitive evaluation a great importance was attached 
to the evaluation of emotional domains, apathy and depression in particular, and quality 
of life.
Ogino et al. [46] assessed cognitive functions by administration of the Wechsler Adult Intel-
ligence Scale-Revised, Wechsler Memory Scale-Revised, and Alzheimer Disease Assessment 
Scale (ADAS) orientation subtest. Saito et al. [64] used an exhaustive and detailed neuropsy-
chological assessment, which included the MMSE for general cognitive function, Digit Span 
and Spatial Span for attention, Word fluency, Trail Making Test A (TMT A) and FAB for execu-
tive function, Object naming subtest for language, the Word recall and Word recognition 
subtests of ADAS for episodic memory and Visual discrimination, Overlapping figures and 
Visual counting tasks for evaluating visuoperceptual and visuospatial functions.
In a recent study by Missori and Currà [67] all the patients underwent a wide neuropsycho-
logical assessment: MMSE, FAB, Rey’s 15 words immediate and delayed recall, Wisconsin 
Card Sorting Test, TMT, Attentive Matrices, Analogies test, and Digit Span forward and back-
ward tasks. However, the authors included only the scores from the MMSE in the analysis 
of the results because the aim of their work was to grossly quantify cognitive impairment in 
patients.
As we can see, most authors have used large neuropsychological battery, but different mea-
sures within the single cognitive domain have been administered in the different studies. 
Therefore the various studies are not immediately comparable and a standardized protocol 
should be needed.
6. Cognitive impairment after shunt surgery
iNPH is considered a potentially reversible dementia and as described above the treatment of 
choice is ventriculo-peritoneal or atrial shunt device placement. When considering the global 
outcome, there is a general agreement about the fact that short-term results are more likely to 
be influenced by shunt-associated risks, while long-term results are more influenced by other 
factors, such as concomitant neurodegenerative and cerebrovascular diseases; the one-year 
post-shunt period can be considered a determinant of long-term results of the treatment [68].
Shunt surgery can help to reduce cognitive impairment, especially if it is performed during 
the early stage of deterioration, as it will be more detailed below; if the pressure is not relieved 
quickly by a shunt patients with severe iNPH will in fact develop overall cognitive impair-
ment [9, 50]. This deterioration is only partially reversible as reported by Andrèn et al. [69], 
who described the effects of waiting for at least 6 months before surgery and compared the 
outcome with that seen in patients who waited for less than 3 months. The patients of the first 
group significantly deteriorated; both groups ameliorated at the same size after surgery, but 
since the symptoms of the patients of the first group had worsened while waiting, their final 
outcome was significantly poorer.
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Indeed, most studies report an improvement after surgery, but there is no general agreement 
neither about cognitive functions are more likely to be restored after shunt placement nor 
about possible indicators with a predictive value.
Iddon et al. [50], as already mentioned, studied 11 patients (5 demented and 6 non-demented); 
the demented patients showed a significant improvement after shunt surgery, whereas in the 
not demented patients who presented frontal deficits no improvement could be detected. The 
same authors suggested that even successful shunt surgery may not alleviate all aspects of 
cognitive impairment.
Thomas et al. [70] reported that verbal memory and psychomotor speed appear to be the func-
tions more likely to respond to shunt surgery; 22 (53.2%) out of 42 patients at least 3 months 
after surgery showed an overall cognitive improvement (defined as a four-point improve-
ment on MMSE or an improvement by 1 standard deviation in 50% of the neuropsychologi-
cal tests) and a significant improvement in tests of verbal memory and psychomotor speed. 
However, in patients who, at baseline, presented impairment of both verbal memory and 
visuoconstructive functions, the cognitive improvement was less pronounced; on this basis 
the authors suggested that baseline cognitive scores may distinguish patients responsive to 
surgery, that is, the greater the impairment the smaller the recovery. Other studies report an 
improvement of memory, frontal lobe, and visuoconstructive functions at 6 months [71] and 
1 year [62] after shunt surgery; in the paper by Mataró et al. [71] a concomitant significant 
increase in the global corpus callosum size on MRI was also reported.
In a series of 47 consecutive patients, Hellstrom et al. [72] reported that most of the wide range 
cognitive functions are typically affected in iNPH improved at 3 months after shunt place-
ment; contrary to the study by Mataró et al. [71] the more severe functional deficits showed 
the greatest improvements, although they were not completely restored to the levels present 
in healthy controls.
Saito et al. [64] found that frontal functions (assessed using the TMT and FAB) were improved 
at 1 year after the shunt procedure in 26 out of 32 patients; the authors excluded that the 
improvement observed could be ascribed to a possible practice effect. Actually, this is an 
important question which can occur when patients are evaluated after a short interval of time.
Other studies have followed the patients for a longer period, identifying as outcomes the evo-
lution toward dementia and the survival. Koivisto et al. [73] in a study with a median follow-
up of 4.8 years, found an increased risk of dementia and cognitive decline even in patients 
who had initially responded to the shunt. At the end of the follow-up period, 117/146 (80%) 
had cognitive decline and 67/146 (46%) clinical dementia, mainly AD and vascular demen-
tia. In a multivariate analysis, memory deficit as a first symptom emerged as a predictor of 
dementia. Interestingly, eight (5%) patients who at baseline had the full triad of symptoms 
presented dementia without any other signs of neurodegenerative or vascular disease.
Golz et al. [74] followed up 147 patients for 6 years after surgery through yearly examina-
tions; 69 died during the follow-up, 61 reached the six-year assessment. Of these 61 patients, 
59% had an excellent outcome, 15% satisfactory benefit, and 26% unsatisfactory results. The 
authors concluded that shunt surgery can be considered a safe procedure with a favorable 
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outcome. However, no cognitive evaluation was performed; the patients were evaluated 
using only a specific scale for iNPH and a Comorbidity Index to account for additional dis-
eases, which could influence the clinical presentation and outcome.
In some studies the response to shunt has been related to the presence/absence of findings 
consistent with Alzheimer pathology on cortical biopsy or CSF sampling, but the results 
are contradictory. Golomb et al. [75] at a mean post-shunt follow-up of 4.3 months, found a 
small but significant improvement in tests of attention and processing speed only in patients 
with a cortical biopsy negative for Alzheimer pathology. These data were confirmed by 
Savolainen et al. [76], who studied 51 patients under 75 years of age with possible iNPH; 
25 of these patients underwent shunt surgery. One year after shunt placement, 72% of the 
patients showed a good recovery in activities of daily living, 58% experienced improved uri-
nary incontinence, and 57% walked better; the positive effects of the shunt were still present 
at 5 years. However, no change on neuropsychological test performances was found, leading 
the authors to conclude that neuropsychological evaluation, and the MMSE in particular, is of 
little value in diagnosing iNPH. Eight patients with shunt and nine without shunt died in the 
course of the five-year follow-up. The patients with a positive biopsy for Alzheimer pathol-
ogy had worsened more than those with a negative biopsy after 1 year, but mortality was not 
increased in these patients.
On the contrary, Pyykko et al. [77] did not find any differences in CSF Aβ levels or tau bio-
markers between shunt-responding and non-responding iNPH patients, the latter, however, 
were older; no identification of a cognitive profile was identified as no formal neuropsycho-
logical evaluation was performed in order to better define the response to shunt placement.
The same results have been obtained by Yasar et al. [78] the presence of AD pathology in 26% 
of the population with iNPH did not significantly influence the clinical response to shunt 
surgery.
Some studies have focused on the caregiver, interpreting a change of caregiver burden as an 
indirect sign of clinical/cognitive modification. A decrease in caregiver burden was reported 
by Kazui et al. [79] in the caregivers of 81 iNPH patients 1 year after the patients underwent 
the shunt procedure; the improvement of cognitive impairment was identified as the major 
factor contributing to the reduced caregiver burden, even though a formal neuropsychologi-
cal evaluation was not performed.
Petersen et al. [80] evaluated the impact of shunt surgery on social function and health-related 
quality of life in 37 patients 6 months after the procedures; non cognitive evaluation was per-
formed. Twenty-four (65%) showed a clinical improvement, while in 31(86%) quality of life 
returned almost within normal range as a consequence of their greater independence. Despite 
these good results, the caregiver burden was reduced only in caregivers to male patients.
In order to better understand the mechanisms underlying iNPH, some authors looked for 
correlations between cognitive changes and metabolic functioning in specific cerebral regions. 
Calcagni et al. [81] performed F-FDG PET/CT scanning 3 days before and 1 week after shunt 
placement in a small group of iNPH patients. After surgery the global glucose rate signifi-
cantly increased in all patients, while the ventricular size did not change. Clinical status and 
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independence in daily life was measured using scales evaluating activities of daily living, gait, 
urinary incontinence, cognition (the modified Rankin scale, the Krauss scale, the Larsson cat-
egorization system, the Stein-Langfitt scale); a relationship between functional data and clini-
cal assessment was found only after surgery, not before, while changes both in FDG uptake 
and in global cognitive functioning measured by MMSE were reported in 3 out of 19 subjects. 
A further study by the same authors [82] confirmed these data. In an earlier study, Dumarey 
et al. [83] observed an improvement of regional blood flow in the bilateral dorsolateral frontal 
and left mesiotemporal cortex in patients who had previously seen to be clinical responders 
to the spinal tap test. All these data show that functional changes occur early than morpho-
logical ones and seem to suggest a prompt metabolic response by neuronal cells possibly 
related to neuronal plasticity. As yet, however, functional imaging does not seem to provide 
prognostic information making it possible to identify patients who will benefit from surgery.
7. iNPH and Alzheimer’s disease
As above reported iNPH can mimic other neurological diseases variously characterized by 
gait disturbances and cognitive impairment, namely vascular dementia with small vessel dis-
ease, dementia with Lewy bodies, Parkinson’s disease and other parkinsonisms. The diagnos-
tic differentiation can be difficult. In this regard, clinical and neuroimaging data are crucial; 
also the lack of response of iNPH patients to antiparkinsonian drugs can help in the diagnosis.
As regard AD, the matter is fairly complex and challenging. Motor disturbances are usually 
absent in AD, at least in the early stages. As for cognitive impairment, as explained in the 
previous section, impairment of frontal lobe-related functions is not frequent in AD, even if 
a “frontal” variant has been described [84]; all types of memory are impaired in AD, while 
recognition memory is relatively preserved in iNPH. On the other hand, an overlapping of 
the two diseases cannot be excluded, this is particularly important when considering the 
response to shunt surgery. From this perspective, many studies have tried to identify biologi-
cal markers both for improving the diagnosis and predicting shunt efficacy.
Savolainen et al. [76] performed cortical biopsy in 223 iNPH patients; 66 subjects presented 
normal brain tissue, while Alzheimer pathology (neuritic plaques) was present in over 40% 
of patients. The authors suggest that these data may explain the unsuccessful recovery of 
many patients after shunt surgery. The presence of positive biopsies for neuritic plaques was 
also reported by Golomb et al. [75]; 81/117 patients with possible iNPH received a structured 
psychiatric interview, out of these 81, 77 were cognitively impaired (Global Deterioration 
Scale- GDS, ≥ 3), out of these 77, 56 received cortical biopsy. Twenty-three patients presented 
neuritic plaques; these subjects with positive biopsies were more cognitively impaired (higher 
GDS and lower MMSE scores) as well as more gait impaired than patients with negative biop-
sies. The prevalence of neuritic plaques increased in parallel with dementia severity from 18% 
for patients with GDS = 3–75% for patients with GDS scores >6. However, in this study the 
concomitant Alzheimer pathology did not strongly influence the clinical response to shunt 
surgery independently by the severity.
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On the contrary, the degree of Alzheimer pathology is reported to be important in predicting 
the response to surgery in the study by Hamilton et al. [85]; out of 37 patients 12 showed a 
negative biopsy, the remaining 25 subjects showed a high percentage (above 60%) not only of 
neuritic plaques but also of neurofibrillary tangles, which indicates the presence of tau pathol-
ogy. Patients with moderate-to-severe Aβ and tau pathology showed more severe baseline 
cognitive impairment and poorer performance postoperatively on NPH symptom severity 
scales and measures of cognition, while patients with mild Alzheimer pathology responded 
well to shunting. The authors suggest that some patients may be relatively unimpaired by the 
presence of cortical Alzheimer pathology; the different results obtained in respect to previous 
studies are explained by the different methods employed.
Leinonen et al. [86] evaluated the predictive value of brain biopsy for the long-term outcome 
of iNPH in 468 patients with possible iNPH; the presence of beta-amyloid was detected in 
197 (42%) patients, and together with tau pathology in 44 cases (9%), but it did not affect the 
survival.
On the other hand, Alzheimer pathology as neuritic plaques can be present also in the brain of 
normal healthy individuals [87]; therefore, in order to ameliorate the differentiation of diag-
nosis, also CSF biological markers have been investigated. The specific combination of both 
low CSF beta-amyloid (Aβ)-42 and elevated CSF phosphorylated tau (P-tau) in fact is con-
sidered the biological signature of Alzheimer’s disease, where low Aβ levels reflect amyloid 
deposition and high tau levels indicate a prevalent non specific neuronal damage [88].
In 2007, Kapaki et al. [89] studied 85 patients subdivided in 67 with AD and 18 with iNPH, and 
72 healthy controls. Aβ-42 levels were significantly decreased in both diseases as compared 
with controls, while P-tau levels were significantly increased only in Alzheimer’s patients; 
therefore the authors concluded that P-tau may be a useful marker in the differentiation of 
iNPH from Alzheimer’s disease.
In the same year Agren-Wilsson et al. [90] studied 62 iNPH patients, 26 patients with subcorti-
cal vascular encephalopathy and 23 healthy controls. The CSF concentration of neurofilament 
light protein was elevated in iNPH and vascular encephalopathy compared with the controls, 
levels of total tau (T-tau), P-tau, and Aβ-42 were lower in iNPH compared with vascular 
encephalopathy and controls; all markers except Aβ-42 were significantly elevated after shunt 
surgery. These results lead the authors to conclude that not a specific marker but the com-
bined pattern of more markers can distinguish iNPH from vascular patients and controls.
Lower CSF levels of both T-tau and P-tau and amyloid precursor protein have been reported 
also by Jeppsson et al. [91] in 28 iNPH patients compared with 20 healthy controls, while 
neurofilament light protein was elevated. After surgery there was an increase; these data have 
been interpreted as due to a reduced periventricular metabolism and axonal degeneration 
rather than to a major cortical damage.
Kang et al. [92] found lower CSF Aβ-42 levels and lower P-tau levels in 35 iNPH patients in 
respect to the control reference values; tau levels correlated with gait disturbance and CSF 
P-tau/Aβ ratios were significantly higher in patients who did not respond to shunt surgery.
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Jingami et al. [93] studied 55 iNPH patients, 20 Alzheimer’s disease patients, 11 patients with 
cortico-basal syndrome, and 7 patients with spino-cerebellar degeneration. Tau levels were 
significantly decreased in iNPH in respect to AD especially in tap test responders patients; the 
authors concluded that CSF tau can be considered useful for differentiation iNPH from AD.
Pyykkö et al. [77] performed both cortical biopsy and CSF sampling in a population of 53 
patients with iNPH, 26 with AD, and 23 with other diagnosis. In iNPH Aβ load in the brain 
biopsy showed a negative correlation with CSF levels of Aβ-42, no differences in markers 
of neuro-inflammation and neuronal damage were found in both iNPH and Alzheimer’s 
patients. No differences between CSF Aβ levels or tau biomarkers in shunt-responding and 
non-responding iNPH patients have been reported, the non-responding patients were how-
ever older.
The results of a recent meta-analysis [94] suggest that iNPH may be associated with sig-
nificantly reduced levels of CSF Aβ42, t-tau and p-tau compared to normal controls, while 
compared to AD both t-tau and p-tau were significantly decreased in iNPH, but CSFAβ42 is 
slightly increased. The data cannot be considered definitive and helpful for the diagnosis and 
the authors conclude that prospective studies are needed to further assess the clinical utility 
of these and other biomarkers in assisting in the diagnosis of iNPH and differentiating it from 
AD and other neurodegenerative disorders.
Actually iNPH CSF profile seems to be different from AD, in particular most studies report 
low CSF tau levels which are in contrast with elevated CSF tau levels in AD. However, the 
results from the literature cannot be considered conclusive. With particular regard to the data 
pre- and post-shunt Graff-Radford [95] observe that CSF biomarkers cannot be considered 
helpful in distinguishing patients with iNPH from those with comorbid AD and rather can 
provide misleading information. The author suggests that the pre-shunt low CSF Aβ42 (and 
other APP fragments) are not necessarily related to Aβ brain deposition similar to what hap-
pens in AD, but rather could be result from impaired clearance; the data of pre-shunt low tau 
proteins levels may have the same explanation. In iNPH in fact the brain is compressed and 
therefore a decrease in interstitial space and APP protein fragment drainage into the CSF may 
be impeded, resulting in low levels of all CSF proteins. Shunting decompresses the brain and 
creates more room for the interstitial space to increase and protein waste fragments to drain 
into the CSF; CSF proteins increase after shunting in fact has been reported. On the other hand 
Graff-Radfford [95] remarks that this hypothesis does not exclude the hypothesis proposed 
by Jeppsson et al. [89] about a reduced periventricular metabolism; prospective amyloid PET 
studies could be needed in order to determine whether this procedure is able to distinguish 
iNPH from comorbid AD.
8. Our experience
As reported in our recent review [96] the classic definition “fronto- subcortical dementia” is 
reductive, because it cannot completely describe the entire clinical spectrum. It is now known 
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that patients with iNPH actually present impairment in broader cognitive domains: attention, 
working memory, episodic memory, visuoperceptual, and visuospatial functions [50, 63–65].
Here we report the results of our experience [97] to confirm this hypothesis. We evaluated 
retrospectively the cognitive profile and its relationship with disease variables in a group of 
subjects with iNPH. We retrospectively studied clinical charts collected from January 2010 
to December 2014, at the Parkinson’s Disease and Movement Disorders Unit of the Istituto 
Neurologico Nazionale “C. Mondino” of Pavia, Italy. A case series of 64 subjects with diag-
nosis of “probable” iNPH was collected. All recruited patients were referred with primary 
diagnoses of “parkinsonism”.
The diagnosis of iNPH was made on the basis of clinical, neuropsychological and neuroimag-
ing features [1]. In particular, as regard neuroimaging, we followed the criteria previously 
reported: ventricular enlargement not entirely attributable to cerebral atrophy or congeni-
tal enlargement (Evans Index >0.3) and the absence of macroscopic obstruction to CSF flow. 
These main aspects had to be accompanied by at least one of the following supportive fea-
tures: enlargement of the temporal horns of the lateral ventricles not entirely attributable to 
hippocampus atrophy; narrowing of the sulci and subarachnoid spaces over the high convex-
ity/midline surface; callosal angle of 40° or more; evidence of altered brain water content, 
including periventricular signal changes on CT and MRI not attributable to microvascular 
ischemic changes or demyelination; an aqueductal or fourth ventricular flow void on MRI.
Evidence of an antecedent event such as head trauma, intracerebral hemorrhage, meningitis, 
or other known causes of secondary hydrocephalus has been excluded as well as other neuro-
logic, psychiatric, or general medical conditions sufficient to explain symptoms.
Fifty-eight healthy elderly, matched for age, sex, and education, recruited among hospital-
ized patients and/or patients’ relatives without neurological disorder or cognitive impair-
ment, represented the normal control group (NC). All patients and NC were examined by a 
neurologist and tested by a neuropsychologist.
Motor symptoms have been evaluated by the Unified Parkinson’s Disease Rating Scale Part 
III (UPDRS III); this scale has been currently applied to measure the motor impairment due to 
parkinsonism and is administered by the clinician [98, 99].
The following neuropsychological tests were administered to evaluate various domains of 
cognition:
• Mini-Mental State Examination (MMSE): general index of cognitive functioning
• Digit Span forward, Word Span and Spatial Span (Corsi’s test) tests: working memory
• Rey’s 15-word test, both immediate and delayed recall: long-term verbal memory
• Logical memory test: long-term verbal memory for structured material
• Raven’s Colored Matrices 47: visuospatial reasoning
• Weigl’s Sorting Test: categorical abstract thinking
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• Frontal Assessment Battery (FAB): fronto-executive functioning
• Attentive matrices: selective attention
• Phonological and semantic fluency: lexical magazine
• Constructive Apraxia: copying and visuospatial abilities.
Age-, gender-, and education-corrected scores were calculated from the raw scores; the cor-
rected score then were transformed into equivalent scores, ranging from 0 (pathological) to 1 
(lower limit of normal) and 2, 3, 4 (normal).
As reported in Table 2, compared to normal group, iNPH patients showed a worst cognitive 
performances in almost all neuropsychological tests, except for Rey’s 15-word test, immediate 
recall, and Logical memory test, which were within the normal range (ANOVA).
Test/subtest iNPH NC P value
Subjects F/M 64 29/35 58 26/32
Age (years) 73.7 ± 7.5
(range 66–81)
76.0 ± 5.8
(range 71–81)
NS
Education (years) 8 ± 5 8 ± 5 NS
Disease duration (months) 40.1 ± 31.8
(range 8–71)
MMSE 21.8 ± 4.9 28.5 ± 1.5 0.000000001
Digit span forward 4.4 ± 0.7 5.1 ± 1.3 0.0008
Word span 3.8 ± 0.7 4.2 ± 0.9 0.01
Spatial span (Corsi’s test) 3.4 ± 1.0 5.0 ± 1.3 0.00000002
Rey’s 15-word test
• Immediate recall
• Delayed recall
31.2 ± 7.5
4.7 ± 3.6
33.1 ± 2.4
7.1 ± 2.3
NS
0.0001
Logical Memory test 6.9 ± 4.3 8.2 ± 3.4 NS
Raven’s Colored Matrices 47 21.0 ± 6.6 25.1 ± 5.3 0.0007
Weigl’s Sorting Test 5.9 ± 2.9 7.2 ± 2.1 0.01
Frontal Assessment Battery (FAB) 11.5 ± 3.6 15.6 ± 1.8 0.00000008
Attentive matrices 34.8 ± 12.1 42 ± 6.9 0.0003
Verbal fluency:
• Phonological
• Semantic
19.9 ± 9.2
12.1 ± 3.4
23.1 ± 4.3
14.0 ± 2.6
0.02
0.002
Constructive Apraxia 10.9 ± 2.6 12.1 ± 1.9 0.009
Table 2. Demographic and neuropsychological profiles: Comparisons between iNPH and NC groups (M ± SD) (ANOVA)].
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When considering the different cognitive domains involved and on the basis of equivalent 
scores, we subdivided the entire iNPH population in the following subgroups:
• Group 1 (G1): 27 patients (42%) with global cognitive impairment, characterized by global 
deficit of cognitive functions, or anyway by widespread deficit.
• Group 2 (G2): 15 patients (24%) with typical deficit in attention and executive abilities 
(fronto-cortical dysfunction).
• Group 3 (G3): 11 patients (17%) with mild cognitive impairment (MCI), single domain (iso-
lated deficit of a single cognitive domain, i.e. memory, attention, visuospatial abilities).
• Group 4 (G4): 11 patients (17%) with no cognitive impairment.
In Table 3, the clinical, demographic, and motor characteristics of the different groups are 
reported (Chi square test).
In G1 the patients were older, with significantly longer disease duration and a more severe 
motor impairment in respect to the other groups (p < 0.00001). UPDRS III total score showed 
significant differences between G2 versus G3 and G4 patients (p < 0.02 and p < 0.0001, respec-
tively). No differences were found between G3 and G4 groups.
The results of this study show that, when comparing with controls, our iNPH whole popu-
lation was impaired in almost all neuropsychological measures; the extent of statistical sig-
nificant varied from test to test, being more pronounced in logical and executive functions. 
Only episodic memory was relatively preserved; these data seem to suggest that memory 
impairment in iNPH is generally milder in respect to the deficit in other functions, executive 
in particular [46].
However, when we consider the different cognitive domains involved, we can identify sub-
groups of patients with different cognitive profiles: about an half of the subjects (42%) in fact 
presented an overall diffuse impairment which can be framed as dementia of mild to  moderate 
G1
Global cognitive 
impairment (27 pts)
G2
Fronto-cortical 
dysfunction (15 pts)
G3
MCI single domain 
(11 pts)
G4
No cognitive 
impairment (11pts)
Sex M/F 13/14 10/5 7/4 5/6
Age (years) 79.3 ± 1.9* 73.7 ± 7.5 70.4 ± 4.2 69.9 ± 3.2
Disease duration 
(months)
54.2 ± 16.8* 40.0 ± 31.0 33.3 ± 13.2 32.4 ± 11.3
UPDRS III 36.6 ± 10.0*
range 47–27
26.3 ± 3.1°+
range 29–22
20.6 ± 8.4
range 29–10
21.4 ± 2.3
range 24–16
*G1 vs. G2, G3 and G4: p < 0.00001; °G2 vs. G3: p < 0.02; +G2 vs. G4: p < 0.0001.
Table 3. Demographic and clinical characteristics of the different iNPH groups (M ± SD) (ANOVA).
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degree, out of not demented patients, only 24% was characterized by fronto-cortical dysfunc-
tion and we also found a subgroup with impairment in a single cognitive domain and even 
patients without any neuropsychological deficit.
Therefore our results are in agreement with the data of the literature about a wide range of 
cognitive pictures in iNPH [50, 63–65, 94]; in particular, the heading of “fronto-subcortical 
dysfunction” is reductive as it cannot completely encompass the different cognitive profiles.
The second important finding of our study is represented by a positive correlation between 
cognition and disease progression; in fact, though cognitive impairment may be absent in 
early cases, its severity undoubtedly increases with older age, disease duration and sever-
ity of motor disturbances, hypothesizing an underlying common physiopathological mecha-
nism. In this view, as our data can suggest, an early shunt surgery could contain not only 
the progression of motor disturbances but also the advance of cognitive impairment in these 
patients.
Our sample was enrolled on the basis of the presence of gait disturbances/parkinsonism and 
because of these symptoms the patients were referred to our Unit; this aspect may represent a 
weakness of the study in term of patient’s enrollment. On the other hand it is well-known that 
motor disorders are the leading presentation of iNPH [1].
In this study, we have administered an exhaustive neuropsychological evaluation in order 
to investigate different cognitive domains; this is crucial to obtain a more detailed cogni-
tive profile, as suggested by different authors [64–66]. In our opinion an accurate cognitive 
characterization before shunt is relevant in terms of outcome measures. Enrolling homoge-
neous population of iNPH may improve the prediction of response to shunt surgery; a longer 
follow-up period and a closer interaction among the different professionals are needed.
9. Conclusions
iNPH remains a complex and underestimated disease. As far cognitive impairment, this has 
commonly been described as fronto-subcortical dementia, but on the basis of the data of the 
literature we can assume that this term is reductive as it does not fully describe the differ-
ent clinical pictures observed with an involvement of many other cognitive domains. Even 
after many years we still agree with the remarks of Iddon et al. in 1999 [50] “There may not 
be one single form of dementia syndrome in NPH but rather, there are varying degrees of 
cognitive change pre-shunt, according to the amount of permanent brain damage that has 
already taken place, compounded by comorbidity factors such as hypertensive cerebral small 
vessel disease”. Undoubtedly, many other variables differently modulate and interfere with 
the disease expression. Moreover, an overlap with other neurodegenerative diseases can exist; 
this may be a complex and prognostic issue and could partly explain both the progression of 
cognitive decline and the absence of amelioration after successful CSF shunt procedures. With 
regard to the possible overlap with AD in particular, the weight of Alzheimer pathology in 
iNPH patients is not clear; studies investigating possible biological markers in fact have failed 
to obtain conclusive results.
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The great variability of clinical pictures in iNPH has to be interpreted also taking into account 
the role of the “cognitive reserve” phenomenon [100]; even partially, this aspect can also con-
tribute to the differences of the response to shunt surgery.
Clinical and neuroimaging data are crucial for the diagnosis and the literature has provided 
guidelines and precise neuroradiological diagnostic criteria. However, there is no general 
agreement about the neuropsychological measures to employ in assessing the condition, as 
the studies reported in the literature used different cognitive tests; this aspect is obviously rel-
evant to the post-shunt follow-up, too. The neuropsychological assessment has to include sen-
sitive and exhaustive measures investigating the different cognitive domains; also patients’ 
quality of life and caregivers’ point of view have to be investigated in particular after shunt 
surgery in order to obtain a more global and sensitive evaluation.
Another important issue is represented by the difficulty to establish with precision the differ-
ent stages in the disease. The studies reported in the literature have been conducted in patients 
with different disease durations and therefore with different degrees of disease severity; this 
makes it difficult to compare the different results and obviously the results after shunt place-
ment may well be negatively affected in patients with more severe or longer lasting disease. 
In particular as regards the shunt procedure, reliable indices predictive of a good response to 
surgery are still lacking; in the studies analyzed different outcome measures were employed 
in different follow-up periods.
We can conclude that there is a need for further studies with a better standardization; longer fol-
low-ups and closer interaction among the different professionals involved are also requested.
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